Triple
T6311256
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novartis |
E141505
|
entity |
| Predicate | notableDrug |
P7501
|
FINISHED |
| Object |
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
|
E584153
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c008d00efc8190a36c05b4b4a3bf4b |
elicitation | completed |
| NER | batch_69c0649d1e048190a3fc7fbce9d2ee57 |
ner | completed |
| NED1 | batch_69c5e461e2ec8190af7198a03edb1ff7 |
ned_source_triple | completed |
| NED2 | batch_69c5e6e40c588190898ad952b71e5b11 |
ned_description | completed |
| NEDg | batch_69c5e66e8b3c8190bd4cd960b91de473 |
nedg | completed |
Created at: March 22, 2026, 4:28 p.m.